Abstract:This study assessed the predictive value of proton nuclear magnetic resonance [1H‐NMR]‐derived serum metabolomics for the prediction of incident heart failure (HF) within the UK Biobank (UKB) cohort. Risk models were generated based on a well‐validated clinical score (Pooled Cohort Equations to Prevent HF [PCP‐HF]), serum metabolomics, or a combination of both. The serum metabolome was highly associated with incident HF, even after adjustment for clinical HF risk. Comparative analysis of risk models revealed strikingly good performance of simple models based solely on age, sex and the serum metabolome, as depicted in a receiver‐operating characteristic curve or emphasized in excellent HF‐free survival stratification in Kaplan–Meier plots (blue shades correspond to risk quintiles, higher risk: more saturated shades). Aims Prediction and early detection of heart failure (HF) is crucial to mitigate its impact on quality of life, survival, and healthcare expenditure. Here, we explored the predictive value of serum metabolomics (168 metabolites detected by proton nuclear magnetic resonance [1H‐NMR] spectroscopy) for incident HF. Methods and results Leveraging data of 68 311 individuals and >0.8 million person‐years of follow‐up from the UK Biobank cohort, we (i) fitted per‐metabolite Cox proportional hazards models to assess individual metabolite associations, and (ii) trained and validated elastic net models to predict incident HF using the serum metabolome. We benchmarked discriminative performance against a comprehensive, well‐validated clinical risk score (Pooled Cohort Equations to Prevent HF [PCP‐HF]). During a median follow‐up of ≈12.3 years, several metabolites showed independent association with incident HF (90/168 adjusting for age and sex, 48/168 adjusting for PCP‐HF). Performance‐optimized risk models effectively retained key predictors representing highly correlated clusters (≈80% feature reduction). Adding metabolomics to PCP‐HF improved predictive performance (Harrel's C: 0.768 vs. 0.755, ΔC = 0.013, [95% confidence interval [CI] 0.004–0.022], continuous net reclassification improvement [NRI]: 0.287 [95% CI 0.200–0.367], relative integrated discrimination improvement [IDI]: 17.47% [95% CI 9.463–27.825]). Models including age, sex and metabolomics performed almost as well as PCP‐HF (Harrel's C: 0.745 vs. 0.755, ΔC = 0.010 [95% CI −0.004 to 0.027], continuous NRI: 0.097 [95% CI −0.025 to 0.217], relative IDI: 13.445% [95% CI −10.608 to 41.454]). Risk and survival stratification was improved by integrating metabolomics. Conclusion Serum metabolomics improves incident HF risk prediction over PCP‐HF. Scores based on age, sex and metabolomics exhibit similar predictive power to clinically‐based models, potentially offering a cost‐effective, standardizable, and scalable single‐domain alternative.

Quantitative Metabolomics Reveals Heart Failure With Midrange Ejection Fraction as a Distinct Phenotype of Heart Failure

Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction

Metabolomic profile for understanding heart failure classifications

Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction

Metabolomic Association and Risk Prediction With Heart Failure in Older Adults

Characteristic of Metabolic Status in Heart Failure and Its Impact in Outcome Perspective

Abstract MP07: Metabolic Signature Improves Heart Failure Risk Prediction In Older Adults

Metabolomic profiling identifies novel metabolites associated with cardiac dysfunction

Targeted metabolomic analysis of serum amino acids in heart failure patients

Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure

Metabolic Disorder in the Progression of Heart Failure.

Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status

[Similarities and differences of myocardial metabolic characteristics between HFpEF and HFrEF mice based on LC-MS/MS metabolomics]

Serum metabolomics improves risk stratification for incident heart failure

Mass Spectrometry Imaging-Based Single-Cell Lipidomics Profiles Metabolic Signatures of Heart Failure

Using Model‐Based Analysis and Physiology‐Informed Machine Learning to Refine the Stratification of Phenotypes in Heart Failure

Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study

Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study

Integrated Machine Learning Approach to Identify Metabolome Fingerprints of Pathological Stages Following Heart Failure Treatment

Association of genetically predicted human metabolomic gene expression with incident heart failure

Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction